Shares Of Goodrx Are Looking Good After Earnings Beat: Here's What You Need To Know

Zinger Key Points
  • Goodrx issues a fourth quarter earnings per share of 7 cents, ahead of the 5 cent estimate.
  • Fourth quarter revenues come in at $184.11 million, which beats consensus estimates of $178.5 million.

Shares of Goodrx Holdings Inc GDRX are trading higher into Tuesday’s after-hours session following the company’s fourth-quarter earnings report. Here’s what investors need to know.

By The Numbers: Goodrx issued fourth-quarter earnings per share of 7 cents, ahead of the 5 cent estimate, on revenues of $184.11 million, which beat consensus estimates of $178.5 million, according to Benzinga Pro.

• Goodrx said it fulfilled the needs of over 7 million people, reflecting an 8% decrease in its monthly active users.

• The company is guiding for first-quarter revenues to be between $181 million and $183 million, mostly ahead of consensus estimates of $181.72 million.

• It sees full-year revenue coming in between $780 million and $790 million, ahead of the $778.01 million estimates.

“We continue to focus on efficiently growing profitability, steady margin improvement, and executing on strong cash conversion,” CEO Karsten Voermann said in a statement.

“We believe our balance sheet maintains a strong cash and liquidity position, providing financial flexibility and aiding our capital allocation priorities to support our realigned organization in driving highly efficient and profitable growth.”

GDRX Price action: Shares of Goodrx are trading up 6.81% higher to $5.65, according to Benzinga Pro.

Read Next: Mark Cuban Says Americans Shouldn't Have To Pick Between Rent, Food Or Medicine

Photo: NYC Russ via Shutterstock

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEarnings BeatsMid CapNewsGuidanceHealth CareAfter-Hours CenterTrading IdeasGeneralprescription drugswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...